A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer

Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules (Basel, Switzerland) Vol. 11; no. 12; p. 1749
Main Authors Wang, Jing-Jing, Siu, Michelle Kwan-Yee, Jiang, Yu-Xin, Leung, Thomas Ho-Yin, Chan, David Wai, Wang, Huo-Gang, Ngan, Hextan Yuen-Sheung, Chan, Karen Kar-Loen
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 23.11.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…